Hallucinations and other psychotic symptoms associated with the use of attention-deficit/ hyperactivity disorder drugs in children

Pediatrics

Volumn 123, Issue 2, 2009, Pages 611-616

  Mosholder, Andrew D ^a   Gelperin, Kate ^a   Hammad, Tarek A ^a   Phelan, Kathleen ^a   Johann Liang, Rosemary ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

Author keywords

ADHD; Adverse drug reactions; Drug safety; Psychiatric issues in primary care

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; MANIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; VISION; CHEMICALLY INDUCED DISORDER; CHILD; FEMALE; MALE; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; HALLUCINATIONS; HUMANS; MALE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 60549084696     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0185     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention. Mental Health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(34): 842-847. Available at: www.cdc.gov/mmwr/ preview/ mmwrhtml/mm5434a2.htm. Accessed November 21, 2008
2. US Food and Drug Administration. Pediatric Advisory Committee Meeting, June 30, 2005. Available at: www.fda.gov/ohrms/ dockets/ac/05/briefing/2005- 4152b2.htm. Accessed November 21, 2008
3. US Food and Drug Administration. Pediatric Advisory Committee Meeting, March 22, 2006. Available at: www.fda.gov/ ohmis/dockets/ac/06/briefing/2006- 4210B-Index.htm. Accessed November 21, 2008
4. FDA MedWatch. Attention deficit hyperactivity disorder (ADHD) drug products: medication guides required to alert patients to possible cardiovascular and psychiatric risks. February 21, 2007. Available at: www.fda.gov/medwatch/safety/ 2007/safety07.htm#ADHD. Accessed November 21, 2008
5. Cephalon, Inc. Provigil prescribing information. Available at: www.provigil.com/Media/PDFs/prescribing-info.pdf. Accessed November 21, 2008
6. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423
7. Gelperin K, Phelan K. Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. FDA Report PID D050243. US Food and Drug Administration, March 3, 2006. Available at: www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4210b-11-01-AdverseEvents.pdf. Accessed November 21, 2008
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245
9. Gross-Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy. Neurology. 2004;63(4):753-754
10. Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J Am Board Fam Prac. 2002;15(6):498-500
11. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry. 1999; 44(8):811-813
12. Henderson TA, Hartman K. Aggression, mania, andhypomania induction associated with atomoxetine. Pediatrics. 2004;114(3): 895-896
13. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149-1152
14. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-1486
15. Ney PG. Psychosis in a child associated with amphetamine administration. Can Med Assoc J. l067;97(17):1026-1029
16. Lucas AR, Weiss M. Methylphenidate hallucinosis. JAMA. 1971;217(8):1079-1081
17. Young JG. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr. 1981;2(2):35-38
18. Bloom AS, Russell L J, Weisskopf B, Blackerby JL. Methyl-phenidate- induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1988;27(1):88-89
19. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002;14(2):219-223